Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE® (trofinetide)
Pipeline
Pipeline
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2026
2025
2024
2023
2022
2021
2020
2019
Older
Mar 13, 2026
Update - Notification of buy-back - NEU
Mar 10, 2026
Update - Notification of buy-back - NEU
Mar 06, 2026
Change of Director's Interest Notice - J Basile
Mar 04, 2026
Update - Notification of buy-back - NEU
Mar 03, 2026
Acadia confirms plan to request CHMP re-examination
Feb 27, 2026
Investor presentation, 27 February 2026
Feb 27, 2026
2025 royalty income A$65m, profit after tax A$30m
Feb 27, 2026
Appendix 4E and 2025 full year accounts
Feb 26, 2026
Acadia reports DAYBUE net sales for 2025 and 2026 guidance
Feb 26, 2026
Pause in Trading
1
2
3
Next
